Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides

Nathan McMahon, Jocelyn Jones, Jennifer Eng, Sunjong Kwon, Young Hwan Chang, Guillaume Thibault, Kwang-Yung Chin, Michel Nederlof, Joe Gray, Summer Gibbs

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by significant tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this network of interactions and have vastly affected how cancer is diagnosed and treated. However, the translation of complex genomic analyses to pathological diagnosis remains challenging using conventional immunofluorescence (IF) staining, which is typically limited to 2-5 antigens. Numerous strategies to increase distinct antigen detection on a single sample have been investigated, but all have deleterious effects on the tissue limiting the maximum number of biomarkers that can be imaged on a single sample and none can be seamlessly integrated into routine clinical workflows. To facilitate ready integration into clinical histopathology, we have developed a novel cyclic IF (cycIF) technology based on antibody conjugated oligonucleotides (Ab-oligos). In situ hybridization of complementary oligonucleotides (oligos) facilitates biomarker labeling for imaging on any conventional fluorescent microscope. We have validated a variety of oligo configurations and their respective signal removal strategies capable of diminishing fluorescent signal to levels of autofluorescence before subsequent staining cycles. Robust signal removal is performed without the employment of harsh conditions or reagents, maintaining tissue integrity and antigenicity for higher dimensionality immunostaining of a single sample. Our platform Ab-oligo cycIF technology uses conventional fluorophores and microscopes, allowing for dissemination to a broad audience and congruent integration into clinical histopathology workflows.

Original languageEnglish (US)
Title of host publicationImaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII
EditorsDaniel L. Farkas, Attila Tarnok, James F. Leary
PublisherSPIE
ISBN (Electronic)9781510624047
DOIs
StatePublished - Jan 1 2019
EventImaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII 2019 - San Francisco, United States
Duration: Feb 4 2019Feb 6 2019

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume10881
ISSN (Print)1605-7422

Conference

ConferenceImaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII 2019
CountryUnited States
CitySan Francisco
Period2/4/192/6/19

Fingerprint

oligonucleotides
Oligonucleotides
staining
antibodies
Antibodies
Workflow
biomarkers
Biomarkers
antigens
Antigens
Staining and Labeling
Technology
Fluorescent Antibody Technique
Microscopes
cancer
microscopes
Tissue
Arsenals
Neoplasms
Modern 1601-history

Keywords

  • Antibody conjugation
  • Biomarker distribution
  • Cyclic immunofluorescence
  • Fluorescence microscopy
  • Oligonucleotide
  • Photocleavable linker
  • Restriction enzyme
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Biomaterials
  • Radiology Nuclear Medicine and imaging

Cite this

McMahon, N., Jones, J., Eng, J., Kwon, S., Chang, Y. H., Thibault, G., ... Gibbs, S. (2019). Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides. In D. L. Farkas, A. Tarnok, & J. F. Leary (Eds.), Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII [108810X] (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 10881). SPIE. https://doi.org/10.1117/12.2510573

Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides. / McMahon, Nathan; Jones, Jocelyn; Eng, Jennifer; Kwon, Sunjong; Chang, Young Hwan; Thibault, Guillaume; Chin, Kwang-Yung; Nederlof, Michel; Gray, Joe; Gibbs, Summer.

Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII. ed. / Daniel L. Farkas; Attila Tarnok; James F. Leary. SPIE, 2019. 108810X (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 10881).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

McMahon, N, Jones, J, Eng, J, Kwon, S, Chang, YH, Thibault, G, Chin, K-Y, Nederlof, M, Gray, J & Gibbs, S 2019, Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides. in DL Farkas, A Tarnok & JF Leary (eds), Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII., 108810X, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 10881, SPIE, Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII 2019, San Francisco, United States, 2/4/19. https://doi.org/10.1117/12.2510573
McMahon N, Jones J, Eng J, Kwon S, Chang YH, Thibault G et al. Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides. In Farkas DL, Tarnok A, Leary JF, editors, Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII. SPIE. 2019. 108810X. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE). https://doi.org/10.1117/12.2510573
McMahon, Nathan ; Jones, Jocelyn ; Eng, Jennifer ; Kwon, Sunjong ; Chang, Young Hwan ; Thibault, Guillaume ; Chin, Kwang-Yung ; Nederlof, Michel ; Gray, Joe ; Gibbs, Summer. / Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides. Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII. editor / Daniel L. Farkas ; Attila Tarnok ; James F. Leary. SPIE, 2019. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE).
@inproceedings{5a214dbb1f214a41b8bf5363d070e504,
title = "Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides",
abstract = "Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by significant tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this network of interactions and have vastly affected how cancer is diagnosed and treated. However, the translation of complex genomic analyses to pathological diagnosis remains challenging using conventional immunofluorescence (IF) staining, which is typically limited to 2-5 antigens. Numerous strategies to increase distinct antigen detection on a single sample have been investigated, but all have deleterious effects on the tissue limiting the maximum number of biomarkers that can be imaged on a single sample and none can be seamlessly integrated into routine clinical workflows. To facilitate ready integration into clinical histopathology, we have developed a novel cyclic IF (cycIF) technology based on antibody conjugated oligonucleotides (Ab-oligos). In situ hybridization of complementary oligonucleotides (oligos) facilitates biomarker labeling for imaging on any conventional fluorescent microscope. We have validated a variety of oligo configurations and their respective signal removal strategies capable of diminishing fluorescent signal to levels of autofluorescence before subsequent staining cycles. Robust signal removal is performed without the employment of harsh conditions or reagents, maintaining tissue integrity and antigenicity for higher dimensionality immunostaining of a single sample. Our platform Ab-oligo cycIF technology uses conventional fluorophores and microscopes, allowing for dissemination to a broad audience and congruent integration into clinical histopathology workflows.",
keywords = "Antibody conjugation, Biomarker distribution, Cyclic immunofluorescence, Fluorescence microscopy, Oligonucleotide, Photocleavable linker, Restriction enzyme, Tumor heterogeneity",
author = "Nathan McMahon and Jocelyn Jones and Jennifer Eng and Sunjong Kwon and Chang, {Young Hwan} and Guillaume Thibault and Kwang-Yung Chin and Michel Nederlof and Joe Gray and Summer Gibbs",
year = "2019",
month = "1",
day = "1",
doi = "10.1117/12.2510573",
language = "English (US)",
series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
publisher = "SPIE",
editor = "Farkas, {Daniel L.} and Attila Tarnok and Leary, {James F.}",
booktitle = "Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII",

}

TY - GEN

T1 - Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides

AU - McMahon, Nathan

AU - Jones, Jocelyn

AU - Eng, Jennifer

AU - Kwon, Sunjong

AU - Chang, Young Hwan

AU - Thibault, Guillaume

AU - Chin, Kwang-Yung

AU - Nederlof, Michel

AU - Gray, Joe

AU - Gibbs, Summer

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by significant tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this network of interactions and have vastly affected how cancer is diagnosed and treated. However, the translation of complex genomic analyses to pathological diagnosis remains challenging using conventional immunofluorescence (IF) staining, which is typically limited to 2-5 antigens. Numerous strategies to increase distinct antigen detection on a single sample have been investigated, but all have deleterious effects on the tissue limiting the maximum number of biomarkers that can be imaged on a single sample and none can be seamlessly integrated into routine clinical workflows. To facilitate ready integration into clinical histopathology, we have developed a novel cyclic IF (cycIF) technology based on antibody conjugated oligonucleotides (Ab-oligos). In situ hybridization of complementary oligonucleotides (oligos) facilitates biomarker labeling for imaging on any conventional fluorescent microscope. We have validated a variety of oligo configurations and their respective signal removal strategies capable of diminishing fluorescent signal to levels of autofluorescence before subsequent staining cycles. Robust signal removal is performed without the employment of harsh conditions or reagents, maintaining tissue integrity and antigenicity for higher dimensionality immunostaining of a single sample. Our platform Ab-oligo cycIF technology uses conventional fluorophores and microscopes, allowing for dissemination to a broad audience and congruent integration into clinical histopathology workflows.

AB - Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by significant tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this network of interactions and have vastly affected how cancer is diagnosed and treated. However, the translation of complex genomic analyses to pathological diagnosis remains challenging using conventional immunofluorescence (IF) staining, which is typically limited to 2-5 antigens. Numerous strategies to increase distinct antigen detection on a single sample have been investigated, but all have deleterious effects on the tissue limiting the maximum number of biomarkers that can be imaged on a single sample and none can be seamlessly integrated into routine clinical workflows. To facilitate ready integration into clinical histopathology, we have developed a novel cyclic IF (cycIF) technology based on antibody conjugated oligonucleotides (Ab-oligos). In situ hybridization of complementary oligonucleotides (oligos) facilitates biomarker labeling for imaging on any conventional fluorescent microscope. We have validated a variety of oligo configurations and their respective signal removal strategies capable of diminishing fluorescent signal to levels of autofluorescence before subsequent staining cycles. Robust signal removal is performed without the employment of harsh conditions or reagents, maintaining tissue integrity and antigenicity for higher dimensionality immunostaining of a single sample. Our platform Ab-oligo cycIF technology uses conventional fluorophores and microscopes, allowing for dissemination to a broad audience and congruent integration into clinical histopathology workflows.

KW - Antibody conjugation

KW - Biomarker distribution

KW - Cyclic immunofluorescence

KW - Fluorescence microscopy

KW - Oligonucleotide

KW - Photocleavable linker

KW - Restriction enzyme

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85065417299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065417299&partnerID=8YFLogxK

U2 - 10.1117/12.2510573

DO - 10.1117/12.2510573

M3 - Conference contribution

T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

BT - Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII

A2 - Farkas, Daniel L.

A2 - Tarnok, Attila

A2 - Leary, James F.

PB - SPIE

ER -